Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

Specimen Handling 441Magnetic Resonance Spectroscopy 340pembrolizumab 286Biopsy 242Carboplatin 228Cisplatin 193Cyclophosphamide 177Paclitaxel 160Nivolumab 152Gemcitabine 147Bevacizumab 123Radiotherapy 120Dexamethasone 110Pemetrexed 101fludarabine 95Fluorouracil 95atezolizumab 90Radiation 90venetoclax 89Docetaxel 88Doxorubicin 86Oxaliplatin 85durvalumab 84Rituximab 83Leucovorin 81Capecitabine 75Prednisone 72Lenalidomide 69X-Rays 67Etoposide 67

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × ravulizumab × 30 days × Clear all
NCT07596784 2026-05-19

Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)

Alexion Pharmaceuticals, Inc.

Phase 3 Not yet recruiting
20 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡